Beyond the early stages: Insights from the ASSURE registry on bioresorbable vascular scaffolds

EuroIntervention

Volumn 11, Issue 2, 2015, Pages 149-156

  Wöhrle, Jochen ^a   Naber, Christoph ^b   Schmitz, Thomas ^b   Schwencke, Carsten ^c   Frey, Norbert ^d   Butter, Christian ^e   Brachmann, Johannes ^f   Ingwersen, Maja ^c   Drabik, Anna ^g   Markovic, Sinisa ^a   Mathey, Detlef G ^c  

^a UNIVERSITY OF ULM   (Germany)

^b ELISABETH KRANKENHAUS ESSEN   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Herzzentrum Brandenburg   (Germany)

^f KLINIKUM COBURG   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bioresorbable vascular scaffold; Coronary artery disease; Percutaneous coronary intervention

Indexed keywords

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR PARAMETERS; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL LUMEN DIAMETER; MORPHOLOGY; OUTCOME ASSESSMENT; REFERENCE VESSEL DIAMETER; REGISTER; RESTENOSIS; REVASCULARIZATION; SAFETY; TARGET LESION REVASCULARISATION; BIODEGRADABLE IMPLANT; CORONARY ANGIOGRAPHY; DRUG ELUTING STENT; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; PROSPECTIVE STUDY; TISSUE SCAFFOLD; TREATMENT OUTCOME; VERY ELDERLY;

CARDIOVASCULAR AGENT; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ABSORBABLE IMPLANTS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; REGISTRIES; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84979846113     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY14M12_10     Document Type: Article

References (16)

1. Bourantas CV, Farooq V, Zhang Y, Muramatsu T, Gogas BD, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia HM, Serruys PW. Circumferential distribution of the neoin-tima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial. EuroIntervention. 2015;10:1299-306.
2. Bourantas CV, Papafaklis MI, Kotsia A, Farooq V, Muramatsu T, Gomez-Lara J, Zhang YJ, Iqbal J, Kalatzis FG, Naka KK, Fotiadis DI, Dorange C, Wang J, Rapoza R, Garcia-Garcia HM, Onuma Y, Michalis LK, Serruys PW. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study. JACC Cardiovasc Interv. 2014;7:315-24.
3. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012;7:1060-1.
4. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vas-cular scaffold for the treatment of de novo coronary artery steno-sis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578-88.
5. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Clinical and intra-vascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart. 2013;99:98-105.
6. Abizaid A, Costa JR Jr, Bartorelli AL, Whitbourn R, van Geuns RJ, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong WF, Sudhir K, Serruys PW. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention. 2015;10:1396-401..
7. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74.
8. Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C, Veldhof S, Regar E, Serruys PW, van Geuns RJ. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vas-cular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH). EuroIntervention. 2014;10:236-40.
9. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW; ABSORB-EXTEND Investigators. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013;6:247-57.
10. Diletti R, Onuma Y, Farooq V, Gomez-Lara J, Brugaletta S, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Smits P, Koolen J, Meredith I, Li D, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol. 2011;58:258-64.
11. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention. 2006;2:286-94.
12. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013;6:914-22.
13. Zhang YJ, Bourantas CV, Muramatsu T, Iqbal J, Farooq V, Diletti R, Campos CA, Onuma Y, Garcia-Garcia HM, Serruys PW. Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention. 2014;10:672-80.
14. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv. 2011;4:535-8.
15. Onuma Y, Ormiston J, Serruys PW. Bioresorbable scaffold technologies. Circ J. 2011;75:509-20.
16. Farooq V, Gomez-Lara J, Brugaletta S, Gogas BD, Garcia-Garcia HM, Onuma Y, van Geuns RJ, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv. 2012;79:880-8.